RhoA inhibitor treatment at acute phase of spinal cord injury may induce neurite outgrowth and synaptogenesis
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Biochemistry and Molecular Biology Inc.
Abstract
The therapeutic use of RhoA inhibitors (RhoAi) has been experimentally tested in spinal cord injury (SCI). In order to decipher the underlying molecular mechanisms involved in such a process, an in vitro neuroproteomicsystems biology platform was developed in which the pan-proteomic profile of the dorsal root ganglia (DRG) cell line ND7/23 DRG was assessed in a large array of culture conditions using RhoAi and/or conditioned media obtained from SCI ex vivo derived spinal cord slices. A fine mapping of the spatio-temporal molecular events of the RhoAi treatment in SCI was performed. The data obtained allow a better understanding of regeneration/degeneration induced above and below the lesion site. Results notably showed a time-dependent alteration of the transcription factors profile along with the synthesis of growth cone-related factors (receptors, ligands, and signaling pathways) in RhoAi treated DRG cells. Furthermore, we assessed in a rat SCI model the in vivo impact of RhoAi treatment administered in situ via alginate scaffold that was combined with FK506 delivery. The improved recovery of locomotion was detected only at the early postinjury time points, whereas after overall survival a dramatic increase of synaptic contacts on outgrowing neurites in affected segments was observed. We validate these results by in vivo proteomic studies along the spinal cord segments from tissue and secreted media analyses, confirming the increase of the synaptogenesis expression factors under RhoAi treatment. Taken together, we demonstrate that RhoAi treatment seems to be useful to stimulate neurite outgrowth in both in vitro as well in vivo environments. However, for in vivo experiments there is a need for sustained delivery regiment to facilitate axon regeneration and promote synaptic reconnections with appropriate target neurons also at chronic phase, which in turn may lead to higher assumption for functional improvement.
Description
Keywords
Analysis of variance, Animals, Axons, Cells, cultured, Disease models, animal, Enzyme inhibitors, Ganglia, spinal, Locomotion, Neuronal outgrowth, Proteomics, Rats, Regeneration, Rho gtp-binding proteins, Spinal cord injuries, Synaptic vesicles, Tacrolimus, Time factors, Transcription factors, Alginic acid, Protein inhibitor, Rhoa guanine nucleotide binding protein, Rhoa guanine nucleotide binding protein inhibitor, Transcription factor, Unclassified drug, Enzyme inhibitor, Rho guanine nucleotide binding protein, Rhoa protein, rat, Animal cell, Animal tissue, Article, Conditioned medium, Controlled study, Dorsal root, Growth cone, Human, Nerve cell, Nerve fiber regeneration, Neurite, Neurite outgrowth, Nonhuman, Overall survival, Priority journal, Rat, Spinal cord injury, Synaptogenesis, Synthesis, Animal, Antagonists and inhibitors, Axon, Cell culture, Disease model, Drug effects, Metabolism, Pathophysiology, Physiology, Spinal ganglion, Synapse vesicle, Time factor